1. Jordan KM, Arden NK, Doherty M et al. EULAR recommendation 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee of international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
2. Van den Berg WB. Pathophisiology of osteoarthritis. Joint Bone Spine 2000; 67: 555–6.
3. Herrero-Beaumont G, Rovati LC. Use of crystalline sulfate in osteoarthritis. Future Rheumatol 2006; 1 (4): 397–414.
4. Friesen RW, Brideau C, Chan CC et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998; 8 (19): 2777–82.
5. Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4 (2): 265–84.
6. Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296 (2): 558–66.
7. Agrawal NG, Porras AG, Matthews CZ еt al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003; 43 (3): 268–76.
8. Инструкция по медицинскому применению препарата Аркоксиа (эторикоксиб), 2008. http://www.vidal.ru/poisk_preparatov/arcoxia.htm.
9. Agrawal NG, Rose MJ, Matthews CZ et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 2003; 43 (10): 1136–48.
10. Cannon CP, Curtis SP, FitzGerald GA et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81.
11. Curtis SP, Ng J, Yu Q et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26 (1): 70–83.
12. Greenwald M, Peloso P, Hasler F et al. Etoricoxib improves pain and function in rheumatoid arthritis patients on background biologic therapy. A&R 2009; 60 (10): suppl., 606.
13. Collantes E, Curtis SP, Lee KW et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002; 3: 10.
14. Gottesdiener K, Schnitzer T, Fisher C et al. Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002; 41 (9): 1052–61.
15. Zacher J, Feldman D, Gerli R et al. Etoricoxib OA study group. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19 (8): 725–36.
16. Yocum D, Fleischmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000; 160: 2947–54.
17. Reginster JY, Malmstrom K, Mehta A et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007; 66 (7): 945–51.
18. Hunsche E, Geling O, Kong SX et al. Impact of etoricoxib, a novel COX-2 inhibitor, on social and emotional quality of life of patients with osteoarthritis. Osteoporosis Int 2002; 13: S20.
19. Cannon CP, Curtis SP, FitzGerald GA et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81.
20. Leung AT, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18: 49–58.
21. Rubin BR, Burton R, Navarra S et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598–606.
22. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 725–33.
23. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21: 715–22.
24. Watson DJ, Bolognese JA, Yu C et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20: 1899–908.
25. Бадокин В.В. Значение воспаления в развитии и течении остеоартроза. Cons. Med. 2009; 11 (9): 91–5.
26. Van Kuijk C et al. The effects of rofecoxib and diclofenac on knee osteoarthritis articular cartilage: the results from one year prospective clinical trials. Ann Rheum Dis 2000; 59 (Suppl. 1): EULAR 2000: 55.